FI3390448T3 - Intravesikaalinen hoito virtsarakon syöpää varten - Google Patents

Intravesikaalinen hoito virtsarakon syöpää varten Download PDF

Info

Publication number
FI3390448T3
FI3390448T3 FIEP16819062.7T FI16819062T FI3390448T3 FI 3390448 T3 FI3390448 T3 FI 3390448T3 FI 16819062 T FI16819062 T FI 16819062T FI 3390448 T3 FI3390448 T3 FI 3390448T3
Authority
FI
Finland
Prior art keywords
composition
antibodies
use according
bladder
treatment method
Prior art date
Application number
FIEP16819062.7T
Other languages
English (en)
Finnish (fi)
Inventor
Kjetil Hestdal
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure Asa filed Critical Photocure Asa
Application granted granted Critical
Publication of FI3390448T3 publication Critical patent/FI3390448T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
FIEP16819062.7T 2015-12-17 2016-12-19 Intravesikaalinen hoito virtsarakon syöpää varten FI3390448T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522311.8A GB201522311D0 (en) 2015-12-17 2015-12-17 Use
PCT/EP2016/081798 WO2017103280A1 (en) 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer

Publications (1)

Publication Number Publication Date
FI3390448T3 true FI3390448T3 (fi) 2024-07-10

Family

ID=55311161

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP16819062.7T FI3390448T3 (fi) 2015-12-17 2016-12-19 Intravesikaalinen hoito virtsarakon syöpää varten

Country Status (13)

Country Link
US (2) US20180371101A1 (cg-RX-API-DMAC7.html)
EP (1) EP3390448B1 (cg-RX-API-DMAC7.html)
JP (1) JP2018538308A (cg-RX-API-DMAC7.html)
KR (1) KR102878726B1 (cg-RX-API-DMAC7.html)
CN (1) CN108699147B (cg-RX-API-DMAC7.html)
AU (1) AU2016372570B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018012116A2 (cg-RX-API-DMAC7.html)
DK (1) DK3390448T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981986T3 (cg-RX-API-DMAC7.html)
FI (1) FI3390448T3 (cg-RX-API-DMAC7.html)
GB (1) GB201522311D0 (cg-RX-API-DMAC7.html)
PL (1) PL3390448T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017103280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
EP3551225A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Antibodies and methods of use thereof
RU2760132C1 (ru) * 2017-12-01 2021-11-22 ЭсБиАй ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Фармацевтическая композиция для усиления противоопухолевого эффекта ингибитора иммунной контрольной точки
KR20250154511A (ko) 2023-03-07 2025-10-28 포토큐어 에이에스에이 방광암 치료

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122006000051I2 (de) 1995-03-10 2010-07-08 Photocure Asa Hoffsveien 48 Ester der 5-Aminolevulinsäure als Mittel zur Photosensibilisierung in der Chemotherapie
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
HUE030807T2 (en) * 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
SG10201603055WA (en) 2012-05-31 2016-05-30 Genentech Inc Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists
JP6954648B2 (ja) * 2015-10-19 2021-10-27 シージー オンコロジー， インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use

Also Published As

Publication number Publication date
PL3390448T3 (pl) 2024-09-16
CA3008548A1 (en) 2017-06-22
JP2018538308A (ja) 2018-12-27
CN108699147B (zh) 2022-11-01
BR112018012116A2 (en) 2018-12-04
US20180371101A1 (en) 2018-12-27
WO2017103280A9 (en) 2017-11-09
DK3390448T3 (da) 2024-07-22
US20190241672A1 (en) 2019-08-08
EP3390448B1 (en) 2024-06-05
AU2016372570B2 (en) 2024-01-18
EP3390448A1 (en) 2018-10-24
RU2018124866A3 (cg-RX-API-DMAC7.html) 2020-02-26
KR20180094988A (ko) 2018-08-24
AU2016372570A1 (en) 2018-07-12
ES2981986T3 (es) 2024-10-14
WO2017103280A1 (en) 2017-06-22
GB201522311D0 (en) 2016-02-03
CN108699147A (zh) 2018-10-23
US11066478B2 (en) 2021-07-20
KR102878726B1 (ko) 2025-10-29
RU2018124866A (ru) 2020-01-17

Similar Documents

Publication Publication Date Title
FI3390448T3 (fi) Intravesikaalinen hoito virtsarakon syöpää varten
DOP2011000045A (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
NZ723369A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
RU2019112029A (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
EA201792541A2 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
EA201991704A2 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
FI3728313T3 (fi) Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä
EA201100778A1 (ru) Гетероциклические замещенные соединения в качестве ингибиторов hif
EA202091514A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR
JP2018538308A5 (cg-RX-API-DMAC7.html)
RU2015104001A (ru) Комбинированная терапия для лечения глиобластомы
AR095197A1 (es) Combinación de un inhibidor de egfr t790m y un inhibidor de egfr para el tratamiento del cáncer pulmonar de células no pequeñas
FI3463436T3 (fi) Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää
JP2020502198A5 (cg-RX-API-DMAC7.html)
RU2014139955A (ru) Прокаспазная комбинированная терапия при глиобластоме
JP2017519006A5 (cg-RX-API-DMAC7.html)
EA202290024A1 (ru) Способы лечения болезни фабри у пациентов с почечной недостаточностью
FI3389717T3 (fi) Neoadjuvanttihoito virtsarakon syöpää varten
WO2020132560A3 (en) Compositions and methods for cancer therapy
PE20221768A1 (es) Inhibidores de egfr
IL320024A (en) Perk inhibitor hc-5404 in combination with anti-pd-1 antibody and/or an antiangiogenetic agent for use in the treatment of cancer
FI3646869T3 (fi) Solunsalpaajahoito atsabisykloyhdisteellä syövän hoitamiseksi
BR112022007349A2 (pt) Homodímero de quinureninase, método para produzir um homodímero de quinureninase peguilado, formulação farmacêutica e método para tratar um sujeito tendo um tumor
PL425038A1 (pl) Nowe peptydowe pochodne płytkopochodnego czynnika wzrostu (PDGF), sposób ich otrzymywania, kompozycja farmaceutyczna oraz zastosowanie
AR134001A1 (es) Tratamiento conjunto que comprende un anticuerpo anti-vegf-a y anti-pd-l1 biespecífico, y una quimioterapia para el tratamiento contra cáncer